FAQ: Quantum BioPharma Ltd.'s Digitally Engineered Growth Model and Neuroprotective Innovations

What is Quantum BioPharma Ltd. and what does it do?

Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) is a biopharmaceutical company building a portfolio of innovative assets and biotech solutions for treating challenging neurodegenerative and metabolic disorders and alcohol misuse disorders. The company operates through a digitally integrated model that merges clinical innovation, consumer health commercialization, and market infrastructure modernization.

What is Lucid-MS and why is it significant?

Lucid-MS is Quantum BioPharma’s flagship neuroprotective program developed with Massachusetts General Hospital to address demyelination in multiple sclerosis. It’s a patented new chemical entity shown to prevent and reverse myelin degradation, the underlying mechanism of multiple sclerosis, in preclinical models, representing a promising approach to treating this challenging neurodegenerative condition.

What is unbuzzd(TM) and how is Quantum BioPharma involved with it?

unbuzzd(TM) is a beverage product originally invented by Quantum BioPharma and now commercialized through Unbuzzd Wellness Inc. (formerly Celly Nutrition Corp.). Quantum BioPharma retains 20.11% ownership of Unbuzzd Wellness Inc. and receives royalty payments of 7% of sales until payments total $250 million, then 3% in perpetuity, while maintaining 100% rights to develop similar products for pharmaceutical and medical uses.

How does Quantum BioPharma’s business model differ from traditional biotech companies?

Quantum BioPharma employs a digitally engineered, multi-vertical growth model that expands beyond traditional R&D into scalable, data-driven operations. The company combines biotech development with consumer health commercialization and advanced trading technologies through its dual listing on Upstream, positioning it as a next-generation public issuer that unites science, transparency, and capital efficiency.

What strategic investments does Quantum BioPharma maintain?

Quantum BioPharma maintains a portfolio of strategic investments through its wholly owned subsidiary, FSD Strategic Investments Inc., which represents loans secured by residential or commercial property. This provides additional financial stability and diversification beyond the company’s core biopharmaceutical operations.

Where can investors find the latest news and updates about Quantum BioPharma?

The latest news and updates relating to QNTM are available in the company’s newsroom at https://ibn.fm/QNTM. Investors can also view the full press release at https://ibn.fm/VIoxb for detailed information about the company’s developments and strategic direction.

What makes Quantum BioPharma a prototype for digitally engineered life sciences enterprises?

Quantum BioPharma serves as a prototype by aligning biotech development with advanced trading and investor-access technologies through its dual listing on Upstream. The company’s digitally integrated approach merges clinical innovation with consumer health commercialization and market infrastructure modernization, creating a comprehensive model for next-generation life sciences operations.

What are the key focus areas for Quantum BioPharma’s research and development?

Quantum BioPharma focuses on developing treatments for challenging neurodegenerative and metabolic disorders and alcohol misuse disorders, with drug candidates in different stages of development. The company’s lead compound, Lucid-MS, specifically targets multiple sclerosis through its wholly owned subsidiary, Lucid Psycheceuticals Inc.